Schizophrenia
Conditions
Keywords
schizophrenia, pimozide, clozapine
Brief summary
This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but continue to experience symptoms. The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing symptoms (such as hearing voices, having trouble in organizing your thoughts, lack of interest in life events and social activities), compared to placebo (an inactive substance, sugar pill), when added to clozapine in patients with schizophrenia. The participant will be asked to come in once a week to meet with the research staff and study doctor. The participant will continue to see your regular clinician during this study for all normal appointments. The participant will remain on your current medications throughout the study. During the study you will be randomly selected to be put on a small dose of Pimozide or placebo.
Detailed description
If you choose to participate, you will first have screening tests to find out if you are eligible. The study physician will do a number of tests including a physical examination, a routine medical history, lab tests for blood and urine, and EKG (to monitor your heart) and interviews about your physical and mental health. At each visit you will complete an EKG (to monitor your heart), vital signs, and discuss how you are feeling with the research staff and doctor. Once a month, we will also conduct a slightly longer interview with you about your symptoms and draw one tube of blood to check your Clozapine level. At the beginning and end of the study, you will do some pencil and paper games called Neurocognitive tests. If you are interested in participating in this study, we will go over it in greater detail with you, including the possible benefits and risks associated with participating. We will make sure you understand the study before you begin. This study is completely voluntary, which means that you can choose to stop participating in the study at any time.
Interventions
DRUGPimozide
half of the subjects are randomized to the active drug group
DRUGplacebo
half of the subjects are randomized to placebo group
Sponsors
Stanley Medical Research Institute
Yale University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of schizophrenia or schizoaffective disorder. * A minimum Brief Psychiatric Rating Scale (BPRS) score of 35 and a BPRS psychotic symptom cluster score of at least 8. * Currently taking clozapine with a blood level between 350-1000 ng/ml and on a stable dose of clozapine for the past 2 weeks. * Able to give informed consent.
Exclusion criteria
* A history of significant medical/neurological disease such as thyroid, renal, hepatic abnormality, seizure disorder. * History of Neuroleptic Malignant Syndrome. * Current substance abuse determined by urine toxicology. * Cardiac arrhythmia, sinus bradycardia (heart rate less than 60/min), sinus tachycardia (heart rate greater than 110/min), supraventricular tachycardia, ventricular tachycardia, Wolff-Parkinson-White Syndrome, first, second, third degree atrioventricular (AV) block, atrial fibrillation, atrial flutter and junctional complexes. in baseline electrocardiogram (EKG). Study doctors will examine the EKGs and consult with an internist/cardiologist as needed. * on EKG: QTc \> 450 ms. * Current use of macrolide antibiotics (e.g., erythromycin, clarithromycin), azole antifungal agents (e.g., ketoconazole, itraconazole), protease inhibitors (e.g., ritonavir, indinavir), nefazodone, and other medications that are associated with prolonged QTc. * Current use of antipsychotics other than clozapine. * Current use of sertraline. * IQ level below 70. * At high risk for suicidal/homicidal behavior. * Pregnancy, lack of birth control for females of childbearing age (female patients must report use of effective method for birth control such as birth control pills, condoms, barrier methods, abstinence or have written statement from their doctors that they are medically sterile). * Non-English speaking.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brief Psychiatric Rating Scale (BPRS) Total Score | Baseline | The Brief Psychiatric Rating Scale (BPRS) is an 18-item instrument. The items are anchored on a 7-point scale (higher rating: greater severity). Total scores range from 18 to 126 (higher score: greater severity). The instrument covers areas including: somatic concerns, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement and disorientation. |
| Scale for the Assessment of Negative Symptoms (SANS) | baseline | The Scale for the Assessment of Negative Symptoms (SANS) is a rating scale to measure negative symptoms in schizophrenia. The scale has 25 items (20 individual and 5 global) rated on scale of 0-5 (higher rating: greater severity). SANS is split into 5 domains, and within each domain separate symptoms are rated from 0 (absent) to 5 (severe). Domains include: Affective Flattening or Blunting, Alogia, Avolition - Apathy, Anhedonia - Asociality, Attention. The total range of the SANS is from 0 to 120. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Verbal Fluency | Baseline | Verbal fluency was measured using the Controlled Word Association Test (COWAT). There is no range for this measure, as it is not a scale. The subjects can generate as many new words as they can, so there is no maximum. The greater the number of words one generates indicates better performance. |
| QTc | Baseline | The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart. ECG machines calculate a corrected QT (QTc). QTc is the corrected QT interval in the EKG. Normal range is from 430-470ms. |
| Processing Speed | Baseline | Processing speed was assessed using using Digit Symbol Coding from the Wechsler Adult Intelligence Scale, Revised (WAIS-R). The tool is used for the assessment of processing speed. The range of scores is 0 to 100- with the higher number indicating greater performance. |
| CGI Severity of Illness Scale (CGI-S) | baseline | CGI Severity of Illness Scale (CGI-S) assesses severity of illness on 1-7 scale. Clinicians' experience is used to gauge the severity of illness from 'normal' (value=1) to 'among the most extremely ill patients' (value=7). The higher rating correlates with more severely ill. |
| Verbal Learning and Memory: List B | Baseline | Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List B: Single Trial. This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back. |
| Trail Making Test: Trail A | Baseline | Working memory by Digit Span and Letter Number Sequencing, and attention/executive functions were measured by the Trail Making Test (Parts A and B). This is an assessment of attention/executive function, it does not have an interpret-able range of scores like a traditional scale. Subjects makes trails on paper against time. |
| Trail Making Test: Trail B | Baseline | The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. ( Arnett, James A.; Seth S. Labovitz (1995). Effect of physical layout in performance of the Trail Making Test. Psychological Assessment 7 (2): 220-221. doi:10.1037/1040-3590.7.2.220. Retrieved 2012-02-22.) Part A is used primarily to examine cognitive processing speed. Part B, in which the subject alternates between numbers and letters, is used to examine executive functioning. (Tombaugh, T.N.T.N (2004). Trail Making test A and B: Normative Data Stratified by Age and Education. Archives of Clinical Neuropsychology : The Official Journal of the National Academy of Neuropsychologists 19 (2): 203-214. doi:10.1016/s0887-6177(03)00039-8. Retrieved 2012-01-10.) |
| Verbal Learning and Memory: List A | Baseline | Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List A: Total Trials (1-5). This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back. |
| CGI Improvement Scale (CGI-I) | Endpoint (12 weeks) | CGI Improvement Scale (CGI-I) higher rating correlates with worsening of condition (vs. improvement with lower rating). The CGI-I is scored from 1 to 7 where 1 = 'very much improved' and 7 = 'very much worse'. Clinicians are asked to rate total improvement in the following manner: ...in your judgement, it is due entirely to drug treatment. Compared to his condition at admission to the project, how much has he changed? |
Countries
United States
Participant flow
Recruitment details
This clinical trial was conducted at the outpatient clinics of the West Haven VA, Connecticut Mental Health Center of Yale Department of Psychiatry, and the Zucker-Hillside Hospital of Long Island Jewish Health Care System, and approved by the respective Institutional Review Boards.
Pre-assignment details
Prior to randomization, a stable dose of clozapine for the past 2 weeks with a blood level of at least 350 ng/ml was targeted. Subjects were stratified as to whether they were receiving psychoactive medications such as mood stabilizers, to ensure that about equal numbers of subjects were randomized based on this treatment profile.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Pimozide Half of the subjects were randomized to placebo group. | 14 |
| Active Pimozide Half of the subjects are randomized to the active drug. | 14 |
| Total | 28 |
Baseline characteristics
| Characteristic | Placebo Pimozide | Active Pimozide | Total |
|---|---|---|---|
| Age, Continuous | 41.5 years STANDARD_DEVIATION 2.8 | 44.3 years STANDARD_DEVIATION 2 | 43.0 years STANDARD_DEVIATION 9 |
| Sex: Female, Male Female | 4 Participants | 4 Participants | 8 Participants |
| Sex: Female, Male Male | 10 Participants | 10 Participants | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 1 / 14 | 1 / 14 |
| serious Total, serious adverse events | 0 / 14 | 0 / 14 |
Outcome results
Primary
Brief Psychiatric Rating Scale (BPRS) Total Score
The Brief Psychiatric Rating Scale (BPRS) is an 18-item instrument. The items are anchored on a 7-point scale (higher rating: greater severity). Total scores range from 18 to 126 (higher score: greater severity). The instrument covers areas including: somatic concerns, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement and disorientation.
Time frame: Endpoint (12 weeks)
Population: Subjects were analyzed intent to treat.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Brief Psychiatric Rating Scale (BPRS) Total Score | 37.9 units on a scale | Standard Error 2.1 |
| Active Pimozide | Brief Psychiatric Rating Scale (BPRS) Total Score | 39.6 units on a scale | Standard Error 2.1 |
Primary
Brief Psychiatric Rating Scale (BPRS) Total Score
The Brief Psychiatric Rating Scale (BPRS) is an 18-item instrument. The items are anchored on a 7-point scale (higher rating: greater severity). Total scores range from 18 to 126 (higher score: greater severity). The instrument covers areas including: somatic concerns, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement and disorientation.
Time frame: Baseline
Population: Subjects were analyzed intent to treat.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Brief Psychiatric Rating Scale (BPRS) Total Score | 44.1 units on a scale | Standard Error 2 |
| Active Pimozide | Brief Psychiatric Rating Scale (BPRS) Total Score | 44.3 units on a scale | Standard Error 2 |
Primary
Scale for the Assessment of Negative Symptoms (SANS)
The Scale for the Assessment of Negative Symptoms (SANS) is a rating scale to measure negative symptoms in schizophrenia. The scale has 25 items (20 individual and 5 global) rated on scale of 0-5 (higher rating: greater severity). SANS is split into 5 domains, and within each domain separate symptoms are rated from 0 (absent) to 5 (severe). Domains include: Affective Flattening or Blunting, Alogia, Avolition - Apathy, Anhedonia - Asociality, Attention. The total range of the SANS is from 0 to 120.
Time frame: Endpoint (12 weeks)
Population: Analyzed intent to treat.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Scale for the Assessment of Negative Symptoms (SANS) | 36.3 units on a scale | Standard Error 5.9 |
| Active Pimozide | Scale for the Assessment of Negative Symptoms (SANS) | 37.3 units on a scale | Standard Error 5.9 |
Primary
Scale for the Assessment of Negative Symptoms (SANS)
The Scale for the Assessment of Negative Symptoms (SANS) is a rating scale to measure negative symptoms in schizophrenia. The scale has 25 items (20 individual and 5 global) rated on scale of 0-5 (higher rating: greater severity). SANS is split into 5 domains, and within each domain separate symptoms are rated from 0 (absent) to 5 (severe). Domains include: Affective Flattening or Blunting, Alogia, Avolition - Apathy, Anhedonia - Asociality, Attention. The total range of the SANS is from 0 to 120.
Time frame: baseline
Population: Analyzed intent to treat.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Scale for the Assessment of Negative Symptoms (SANS) | 44.3 units on a scale | Standard Error 5.9 |
| Active Pimozide | Scale for the Assessment of Negative Symptoms (SANS) | 38.5 units on a scale | Standard Error 5.8 |
Secondary
CGI Improvement Scale (CGI-I)
CGI Improvement Scale (CGI-I) higher rating correlates with worsening of condition (vs. improvement with lower rating). The CGI-I is scored from 1 to 7 where 1 = 'very much improved' and 7 = 'very much worse'. Clinicians are asked to rate total improvement in the following manner: ...in your judgement, it is due entirely to drug treatment. Compared to his condition at admission to the project, how much has he changed?
Time frame: Endpoint (12 weeks)
Population: Analyzed intent to treat.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | CGI Improvement Scale (CGI-I) | 2.8 units on a scale | Standard Error 1 |
| Active Pimozide | CGI Improvement Scale (CGI-I) | 3.4 units on a scale | Standard Error 0.5 |
Secondary
CGI Severity of Illness Scale (CGI-S)
CGI Severity of Illness Scale (CGI-S) assesses severity of illness on 1-7 scale. Clinicians' experience is used to gauge the severity of illness from 'normal' (value=1) to 'among the most extremely ill patients' (value=7). The higher rating correlates with more severely ill.
Time frame: Endpoint (12 weeks)
Population: Analyzed intent to treat.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | CGI Severity of Illness Scale (CGI-S) | 3.9 units on a scale | Standard Error 0.8 |
| Active Pimozide | CGI Severity of Illness Scale (CGI-S) | 3.9 units on a scale | Standard Error 0.5 |
Secondary
CGI Severity of Illness Scale (CGI-S)
CGI Severity of Illness Scale (CGI-S) assesses severity of illness on 1-7 scale. Clinicians' experience is used to gauge the severity of illness from 'normal' (value=1) to 'among the most extremely ill patients' (value=7). The higher rating correlates with more severely ill.
Time frame: baseline
Population: Analyzes intent to treat.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | CGI Severity of Illness Scale (CGI-S) | 4.1 units on a scale | Standard Error 0.5 |
| Active Pimozide | CGI Severity of Illness Scale (CGI-S) | 4.0 units on a scale | Standard Error 0.9 |
Secondary
Processing Speed
Processing speed was assessed using using Digit Symbol Coding from the Wechsler Adult Intelligence Scale, Revised (WAIS-R). The tool is used for the assessment of processing speed. The range of scores is 0 to 100- with the higher number indicating greater performance.
Time frame: Endpoint (12 weeks)
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Processing Speed | 46.5 units on a scale | Standard Deviation 4.7 |
| Active Pimozide | Processing Speed | 42.8 units on a scale | Standard Deviation 5 |
Secondary
Processing Speed
Processing speed was assessed using using Digit Symbol Coding from the Wechsler Adult Intelligence Scale, Revised (WAIS-R). The tool is used for the assessment of processing speed. The range of scores is 0 to 100- with the higher number indicating greater performance.
Time frame: Baseline
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Processing Speed | 48.8 units on a scale | Standard Deviation 4.6 |
| Active Pimozide | Processing Speed | 43.3 units on a scale | Standard Deviation 4.9 |
Secondary
QTc
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart. ECG machines calculate a corrected QT (QTc). QTc is the corrected QT interval in the EKG. Normal range is from 430-470ms.
Time frame: Endpoint (12 weeks)
Population: Intention to Treat
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | QTc | 412.9 ms | Standard Deviation 5 |
| Active Pimozide | QTc | 420.3 ms | Standard Deviation 5.2 |
Secondary
QTc
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart. ECG machines calculate a corrected QT (QTc). QTc is the corrected QT interval in the EKG. Normal range is from 430-470ms.
Time frame: Baseline
Population: Intention to Treat
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | QTc | 408.8 ms | Standard Deviation 5 |
| Active Pimozide | QTc | 412.3 ms | Standard Deviation 5.1 |
Secondary
Trail Making Test: Trail A
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. ( Arnett, James A.; Seth S. Labovitz (1995). Effect of physical layout in performance of the Trail Making Test. Psychological Assessment 7 (2): 220-221. doi:10.1037/1040-3590.7.2.220. Retrieved 2012-02-22.) Part A is used primarily to examine cognitive processing speed. Part B, in which the subject alternates between numbers and letters, is used to examine executive functioning. (Tombaugh, T.N.T.N (2004). Trail Making test A and B: Normative Data Stratified by Age and Education. Archives of Clinical Neuropsychology : The Official Journal of the National Academy of Neuropsychologists 19 (2): 203-214. doi:10.1016/s0887-6177(03)00039-8. Retrieved 2012-01-10.)
Time frame: Endpoint (12 weeks)
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Trail Making Test: Trail A | 3.6 seconds | Standard Deviation 0.1 |
| Active Pimozide | Trail Making Test: Trail A | 3.8 seconds | Standard Deviation 0.1 |
Secondary
Trail Making Test: Trail A
Working memory by Digit Span and Letter Number Sequencing, and attention/executive functions were measured by the Trail Making Test (Parts A and B). This is an assessment of attention/executive function, it does not have an interpret-able range of scores like a traditional scale. Subjects makes trails on paper against time.
Time frame: Baseline
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Trail Making Test: Trail A | 3.7 seconds | Standard Deviation 0.1 |
| Active Pimozide | Trail Making Test: Trail A | 3.8 seconds | Standard Deviation 0.1 |
Secondary
Trail Making Test: Trail B
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. ( Arnett, James A.; Seth S. Labovitz (1995). Effect of physical layout in performance of the Trail Making Test. Psychological Assessment 7 (2): 220-221. doi:10.1037/1040-3590.7.2.220. Retrieved 2012-02-22.) Part A is used primarily to examine cognitive processing speed. Part B, in which the subject alternates between numbers and letters, is used to examine executive functioning. (Tombaugh, T.N.T.N (2004). Trail Making test A and B: Normative Data Stratified by Age and Education. Archives of Clinical Neuropsychology : The Official Journal of the National Academy of Neuropsychologists 19 (2): 203-214. doi:10.1016/s0887-6177(03)00039-8. Retrieved 2012-01-10.)
Time frame: Endpoint (12 weeks)
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Trail Making Test: Trail B | 4.6 seconds | Standard Deviation 0.2 |
| Active Pimozide | Trail Making Test: Trail B | 4.9 seconds | Standard Deviation 0.2 |
Secondary
Trail Making Test: Trail B
The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. ( Arnett, James A.; Seth S. Labovitz (1995). Effect of physical layout in performance of the Trail Making Test. Psychological Assessment 7 (2): 220-221. doi:10.1037/1040-3590.7.2.220. Retrieved 2012-02-22.) Part A is used primarily to examine cognitive processing speed. Part B, in which the subject alternates between numbers and letters, is used to examine executive functioning. (Tombaugh, T.N.T.N (2004). Trail Making test A and B: Normative Data Stratified by Age and Education. Archives of Clinical Neuropsychology : The Official Journal of the National Academy of Neuropsychologists 19 (2): 203-214. doi:10.1016/s0887-6177(03)00039-8. Retrieved 2012-01-10.)
Time frame: Baseline
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Trail Making Test: Trail B | 4.6 seconds | Standard Deviation 0.2 |
| Active Pimozide | Trail Making Test: Trail B | 4.9 seconds | Standard Deviation 0.2 |
Secondary
Verbal Fluency
Verbal fluency was measured using the Controlled Word Association Test (COWAT). There is no range for this measure, as it is not a scale. The subjects can generate as many new words as they can, so there is no maximum. The greater the number of words one generates indicates better performance.
Time frame: Endpoint (12 weeks)
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Verbal Fluency | 12.3 words | Standard Deviation 1.5 |
| Active Pimozide | Verbal Fluency | 11.1 words | Standard Deviation 1.5 |
Secondary
Verbal Fluency
Verbal fluency was measured using the Controlled Word Association Test (COWAT). There is no range for this measure, as it is not a scale. The subjects can generate as many new words as they can, so there is no maximum. The greater the number of words one generates indicates better performance.
Time frame: Baseline
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Verbal Fluency | 12.2 words | Standard Deviation 1.4 |
| Active Pimozide | Verbal Fluency | 10.5 words | Standard Deviation 1.5 |
Secondary
Verbal Learning and Memory: List A
Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List A: Total Trials (1-5). This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.
Time frame: Endpoint (12 weeks)
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Verbal Learning and Memory: List A | 38.0 words | Standard Deviation 4.8 |
| Active Pimozide | Verbal Learning and Memory: List A | 32.3 words | Standard Deviation 4.2 |
Secondary
Verbal Learning and Memory: List A
Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List A: Total Trials (1-5). This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.
Time frame: Baseline
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Verbal Learning and Memory: List A | 40.0 words | Standard Deviation 3.3 |
| Active Pimozide | Verbal Learning and Memory: List A | 26.5 words | Standard Deviation 2.8 |
Secondary
Verbal Learning and Memory: List B
Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List B: Single Trial. This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.
Time frame: Endpoint (12 weeks)
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Verbal Learning and Memory: List B | 3.4 words | Standard Deviation 0.6 |
| Active Pimozide | Verbal Learning and Memory: List B | 3.9 words | Standard Deviation 0.6 |
Secondary
Verbal Learning and Memory: List B
Verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) List B: Single Trial. This assessment consists of a list of words that the subject repeats back, it does not have an interpret-able range of scores like a traditional scale. Scores are based on number of words repeated back.
Time frame: Baseline
Population: Intent to Treat Analysis
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Pimozide | Verbal Learning and Memory: List B | 3.8 words | Standard Deviation 0.4 |
| Active Pimozide | Verbal Learning and Memory: List B | 3.5 words | Standard Deviation 0.4 |